[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34.
https://doi.org/10.3322/caac.21551
|
[2]
|
Thrift, A.P. and El-Serag, H.B. (2020) Burden of Gastric Cancer. Clinical Gastroenterology and Hepatology, 18, 534-542. https://doi.org/10.1016/j.cgh.2019.07.045
|
[3]
|
Sitarz, R., Skierucha, M., Mielko, J., Offerhaus, G.J.A., Maciejewski, R. and Polkowski, W.P. (2018) Gastric Cancer: Epidemiology, Prevention, Classification, and Treatment. Cancer Management and Research, 10, 239-248.
https://doi.org/10.2147/CMAR.S149619
|
[4]
|
Machlowska, J., Puculek, M., Sitarz, M., Terlecki, P., Maciejewski, R. and Sitarz, R. (2019) State of the Art for Gastric Signet Ring Cell Carcinoma: From Classification, Prognosis, and Genomic Characteristics to Specified Treatments. Cancer Management and Research, 11, 2151-2161. https://doi.org/10.2147/CMAR.S188622
|
[5]
|
Matsuoka, T. and Yashiro, M. (2018) Biomarkers of Gastric Cancer: Current Topics and Future Perspective. World Journal of Gastroenterology, 24, 2818-2832. https://doi.org/10.3748/wjg.v24.i26.2818
|
[6]
|
Wu, D., Zhang, P., Ma, J., Xu, J., Yang, L., Xu, W., et al. (2019) Serum Biomarker Panels for the Diagnosis of Gastric Cancer. Cancer Medicine, 8, 1576-1583. https://doi.org/10.1002/cam4.2055
|
[7]
|
Shigeyasu, K., Toden, S., Zumwalt, T.J., Okugawa, Y. and Goel, A. (2017) Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers. Clinical Cancer Research, 23, 2391-2399.
https://doi.org/10.1158/1078-0432.CCR-16-1676
|
[8]
|
Zheng, T.H., Zhao, J.L. and Guleng, B. (2015) Advances in Molecular Biomarkers for Gastric Cancer. Critical Reviews in Eukaryotic Gene Expression, 25, 299-305. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2015014360
|
[9]
|
Konforte, D. and Diamandis, E.P. (2013) Is Early Detection of Cancer with Circulating Biomarkers Feasible? Clinical Chemistry, 59, 35-37. https://doi.org/10.1373/clinchem.2012.184903
|
[10]
|
Correa, P. (2010) Serum Pepsinogens in Gastric Cancer Screening. Digestive Diseases and Sciences, 55, 2123-2125.
https://doi.org/10.1007/s10620-010-1248-8
|
[11]
|
Shimada, H., Noie, T., Ohashi, M., Oba, K. and Takahashi, Y. (2014) Clinical Significance of Serum Tumor Markers for Gastric Cancer: A Systematic Review of Literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 17, 26-33. https://doi.org/10.1007/s10120-013-0259-5
|
[12]
|
Jing, J.X., Xu, X.Q., Du, L.L., Tian, B.G., Sun, T., Zhao, X.W., et al. (2013) Clinical Assessment and Prognostic Evaluation of Tumor Markers in Patients with Gastric Cancer. The International Journal of Biological Markers, 28, 192-200. https://doi.org/10.5301/JBM.5000023
|
[13]
|
Sun, Z. and Zhang, N. (2014) Clinical Evaluation of CEA, CA19-9, CA72-4 and CA125 in Gastric Cancer Patients with Neoadjuvant Chemotherapy. World Journal of Surgical Oncology, 12, 397-400.
https://doi.org/10.1186/1477-7819-12-397
|
[14]
|
Mariampillai, A.I., Cruz, J.P.D., Suh, J., Sivapiragasam, A., Nevins, K. and Hindenburg, A.A. (2017) Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries. Anticancer Research, 37, 3649-3656.
|
[15]
|
Johnson, V.G., Schlom, J., Paterson, A.J., Bennett, J., Magnani, J.L. and Colcher, D. (1986) Analysis of a Human Tumor-Associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3. Cancer Research, 46, 850-857.
|
[16]
|
Zhao, B., Zhang, M., Liu, D., Ren, Y., Xie, J., Liang, Y., et al. (2018) Establishment of Reference Interval for the Tumour Marker Serum CYFRA 21-1 in Healthy Chinese Han Ethnic Adults. Scandinavian Journal of Clinical and Laboratory Investigation, 78, 171-174. https://doi.org/10.1080/00365513.2018.1426105
|
[17]
|
Yang, J., Tang, A., Ma, J., Sun, X. and Ming, L. (2019) The Reference Intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1. Scandinavian Journal of Clinical and Laboratory Investigation, 79, 71-74.
https://doi.org/10.1080/00365513.2018.1555855
|
[18]
|
Liang, Y., Wang, W., Fang, C., Raj, S.S., Hu, W.M., Li, Q.W., et al. (2016) Clinical Significance and Diagnostic Value of Serum CEA, CA19-9 and CA72-4 in Patients with Gastric Cancer. Oncotarget, 7, 49565-49573.
https://doi.org/10.18632/oncotarget.10391
|
[19]
|
Chen, C., Chen, Q., Zhao, Q., Liu, M. and Guo, J. (2017) Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer. Annals of Clinical & Laboratory Science, 47, 260-263.
|
[20]
|
Yu, J., Zhang, S. and Zhao, B. (2016) Differences and Correlation of Serum CEA, CA19-9 and CA72-4 in Gastric Cancer. Molecular and Clinical Oncology, 4, 441-449. https://doi.org/10.3892/mco.2015.712
|